0.53%
13.80%
22.37%
20.63%
19.91%
11.15%
25.18%
AI Spotlight on HIK
Company Description
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms.It operates through three segments: Injectables, Generics, and Branded.
The Injectables segment provides generic injectable products primarily for use in hospitals.The Generics segment offers oral and other non-injectable generic products for the retail market.The Branded segment offers branded generics and in-licensed products to retail and hospital markets.
The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory.It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally.The company was founded in 1978 and is based in London, the United Kingdom.
Market Data
| Last Price | 2292 |
| Change Percentage | 0.53% |
| Open | 2270 |
| Previous Close | 2280 |
| Market Cap ( Millions) | 5086 |
| Volume | 1187304 |
| Year High | 2296 |
| Year Low | 1750 |
| M A 50 | 2018.38 |
| M A 200 | 1948.24 |
Financial Ratios
| FCF Yield | 6.82% |
| Dividend Yield | 2.70% |
| ROE | 12.71% |
| Debt / Equity | 55.82% |
| Net Debt / EBIDTA | 123.22% |
| Price To Book | 2.78 |
| Price Earnings Ratio | 22.31 |
| Price To FCF | 14.66 |
| Price To sales | 2.09 |
| EV / EBITDA | 8.7 |
News
- Jan -14 - Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg
- Dec -29 - Is Hikma Pharmaceuticals PLC (HIK.L) Among the U.K. Dividend Aristocrats for 2024?
- Dec -20 - Hikma Pharmaceuticals PLC's (LON:HIK) Stock Is Going Strong: Have Financials A Role To Play?
- Nov -23 - Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 95% Above Its Share Price
- Aug -20 - Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day
- Aug -15 - KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months
- Aug -15 - We Think Hikma Pharmaceuticals' (LON:HIK) Robust Earnings Are Conservative
- Aug -12 - Hikma Pharmaceuticals (HKMPF) Upgraded to Buy: Here's What You Should Know
- Aug -11 - Hikma Pharmaceuticals PLC Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next
- Aug -10 - Hikma Pharmaceuticals First Half 2024 Earnings: Beats Expectations
- Aug -08 - Hikma Pharmaceuticals shares surge on upbeat guidance
- Jul -12 - Does The Market Have A Low Tolerance For Hikma Pharmaceuticals PLC's (LON:HIK) Mixed Fundamentals?
- Jun -03 - An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 35% Undervalued
- May -10 - Stocks to watch this week: Burberry, Vodafone, BT and Walmart
- Apr -26 - Stocks to watch this week: Amazon, Apple, Anglo American and Novo Nordisk
- Apr -15 - With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns
- Feb -26 - Merck's Bridion faces generic threat from drugmaker Hikma
- Feb -21 - Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility
- Feb -08 - High-dose opioid reversal spray no better than lower dose in field, US study finds
- Feb -05 - Hikma announces US launch of COMBOGESIC® IV
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Injectables
Expected Growth : 5 %
What the company do ?
Hikma Pharmaceuticals PLC's Injectables segment offers a range of sterile injectable products, including antibiotics, oncology, and pain management medications.
Why we expect these perspectives ?
Hikma Pharmaceuticals PLC's Injectables segment growth is driven by increasing demand for affordable and accessible healthcare, expansion into emerging markets, and a strong pipeline of generic and branded products. Additionally, strategic partnerships and acquisitions, as well as investments in manufacturing capabilities and quality control, contribute to the segment's growth.
Segment n°2 -> Generics
Expected Growth : 3 %
What the company do ?
Generics from Hikma Pharmaceuticals PLC refers to affordable, high-quality generic medicines that are bioequivalent to branded products, offering cost-effective alternatives for patients.
Why we expect these perspectives ?
Hikma Pharmaceuticals PLC's generics segment growth is driven by increasing demand for affordable medicines, strategic partnerships, and expansion into emerging markets. Additionally, the company's strong pipeline of products and investments in R&D are expected to contribute to its growth. Furthermore, the rising prevalence of chronic diseases and an aging population are also driving demand for generics.
Segment n°3 -> Branded
Expected Growth : 4 %
What the company do ?
Branded is a segment from Hikma Pharmaceuticals PLC that focuses on developing and commercializing branded generics and in-licensed products in the Middle East and North Africa.
Why we expect these perspectives ?
Hikma Pharmaceuticals PLC's branded segment growth is driven by increasing demand for its specialty products, expansion into new markets, and strategic partnerships. Additionally, the company's focus on R&D and product launches has contributed to its growth. Furthermore, the company's strong presence in the Middle East and North Africa region has also driven growth.
Segment n°4 -> Others
Expected Growth : 2 %
What the company do ?
Others from Hikma Pharmaceuticals PLC refers to the remaining business segments, including Injectables, which manufactures and markets injectable products, and the Branded business, which markets branded generics and in-licensed products.
Why we expect these perspectives ?
Hikma Pharmaceuticals PLC's growth is driven by its strong presence in the MENA region, diversified product portfolio, and strategic acquisitions. The company's focus on generics and injectables, as well as its partnerships with multinational companies, have contributed to its growth. Additionally, Hikma's investment in R&D and its ability to capitalize on industry trends, such as the shift towards value-added medicines, have also supported its growth.
Hikma Pharmaceuticals Plc Products
| Product Range | What is it ? |
|---|---|
| Branded Generics | Hikma's branded generics portfolio includes a range of products that are marketed and sold under their own brand names, often in partnership with pharmaceutical companies. |
| Injectables | Hikma's injectables portfolio includes a range of products used in hospitals and clinics, including antibiotics, analgesics, and anesthetics. |
| Generics | Hikma's generics portfolio includes a range of products that are bioequivalent to branded products, but at a lower cost. |
| APIs (Active Pharmaceutical Ingredients) | Hikma's API portfolio includes a range of active pharmaceutical ingredients used in the manufacture of pharmaceutical products. |
| R&D Services | Hikma's R&D services include contract research and development services for pharmaceutical companies. |
Hikma Pharmaceuticals PLC's Porter Forces
Threat Of Substitutes
Hikma Pharmaceuticals PLC operates in a highly regulated industry, and the threat of substitutes is moderate due to the presence of alternative treatments and generic drugs.
Bargaining Power Of Customers
The bargaining power of customers is low due to the fragmented nature of the pharmaceutical industry, and the lack of concentration among buyers.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate due to the presence of a few large suppliers of raw materials and the dependence of Hikma Pharmaceuticals PLC on these suppliers.
Threat Of New Entrants
The threat of new entrants is low due to the high barriers to entry in the pharmaceutical industry, including regulatory hurdles and the need for significant investment in research and development.
Intensity Of Rivalry
The intensity of rivalry is high due to the presence of several established players in the pharmaceutical industry, and the need for Hikma Pharmaceuticals PLC to compete on price, quality, and innovation.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 35.14% |
| Debt Cost | 6.16% |
| Equity Weight | 64.86% |
| Equity Cost | 6.16% |
| WACC | 6.16% |
| Leverage | 54.19% |
Hikma Pharmaceuticals PLC : Quality Control
Hikma Pharmaceuticals PLC passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IPN.PA | Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors … |
| ALM.MC | Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for … |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North … |
| SFZN.SW | Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral … |
| ALVO | Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ipsen
A-Score
1-Year Total Return ->
🥈
Hikma Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
Almirall
A-Score
1-Year Total Return ->
4
Siegfried Holding
A-Score
1-Year Total Return ->
5
Sobi
A-Score
1-Year Total Return ->
6
